Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The HONEYPOT randomized controlled trial statistical analysis plan.
Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, Hawley CM, Johnson DW. Pascoe EM, et al. Among authors: scaria a. Perit Dial Int. 2013 Jul-Aug;33(4):426-35. doi: 10.3747/pdi.2012.00310. Perit Dial Int. 2013. PMID: 23843589 Free PMC article. Clinical Trial.
Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.
Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM; HONEYPOT Study Collaborative Group. Johnson DW, et al. Among authors: scaria a. Lancet Infect Dis. 2014 Jan;14(1):23-30. doi: 10.1016/S1473-3099(13)70258-5. Epub 2013 Oct 10. Lancet Infect Dis. 2014. PMID: 24119840 Clinical Trial.
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group. Johnson DW, et al. Among authors: scaria a. Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10. Am J Kidney Dis. 2015. PMID: 25115616 Clinical Trial.
The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.
Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group. Zhang L, et al. Among authors: scaria a. Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 4. Redox Rep. 2016. PMID: 26083328 Free PMC article.
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED Study Team. Viecelli AK, et al. Among authors: scaria a. Nephrology (Carlton). 2016 Mar;21(3):217-28. doi: 10.1111/nep.12573. Nephrology (Carlton). 2016. PMID: 26205903 Free article. Clinical Trial.
The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.
Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW; HONEYPOT Study Collaborative Group. Zhang L, et al. Among authors: scaria a. Perit Dial Int. 2015 Dec;35(7):712-21. doi: 10.3747/pdi.2014.00206. Epub 2015 Jul 29. Perit Dial Int. 2015. PMID: 26224790 Free PMC article. Clinical Trial.
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group. Badve SV, et al. Among authors: scaria a. Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5. eCollection 2015. Can J Kidney Health Dis. 2015. PMID: 26284153 Free PMC article.
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.
Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group. Roberts MA, et al. Among authors: scaria a. Am J Kidney Dis. 2016 Jun;67(6):902-11. doi: 10.1053/j.ajkd.2015.10.029. Epub 2015 Dec 22. Am J Kidney Dis. 2016. PMID: 26717861 Clinical Trial.
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group. Gummer J, et al. Among authors: scaria a. Nephrology (Carlton). 2017 Jul;22(7):548-554. doi: 10.1111/nep.12815. Nephrology (Carlton). 2017. PMID: 27171136 Clinical Trial.
88 results